Search for: "Teva Neuroscience, Inc." Results 1 - 10 of 10
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Sep 2020, 7:06 am by Peter Briccetti
The U.S. government filed a False Claims Act case against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. [read post]
13 Oct 2014, 8:46 pm by Patent Docs
Mylan Pharmaceuticals Inc. et al. 1:14-cv-00167; filed October 7, 2014 in the Northern District of West Virginia • Plaintiffs: Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.; Teva Neuroscience, Inc.; Yeda Research and Development Co., Ltd. [read post]
30 Aug 2020, 10:19 am by Ben Vernia
According to DOJ’s press release: The United States has filed a False Claims Act complaint against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. [read post]
24 Apr 2016, 9:02 pm by Patent Docs
Biocon Ltd. et al. 1:16-cv-00278; filed April 19, 2015 in the District Court of Delaware • Plaintiffs: Teva Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd.; Teva Neuroscience Inc; Yeda Research and Development Co Ltd. [read post]
12 Oct 2018, 1:24 pm by Lawrence B. Ebert
Delaware of invalidity of claims:Plaintiffs-Appellants Teva Pharmaceuticals USA,Inc., Teva Pharmaceutical Industries, Ltd., Teva Neuroscience,Inc., and Yeda Research and Development Co. [read post]
26 Jun 2011, 8:22 pm by Patent Docs
Teva Neuroscience, Inc. et al. v. [read post]
29 Jun 2011, 3:34 am by Marie Louise
(Patent Docs) Azilect (Rasagiline) – US: Patent infringement complaint in response to Para IV certification: Teva Neuroscience, Inc. et al. v. [read post]
15 Jun 2011, 4:56 am by Marie Louise
(Patent Docs) Azilect (Rasagiline) – US: Patent infringement complaint filed in response to Para IV certification: Teva Neuroscience, Inc. et al. v. [read post]
14 Dec 2010, 7:06 pm by FDABlog HPM
” FDA’s five criteria for assessing active ingredient sameness with respect to generic LOVENOX were also raised in a December 10th citizen petition submitted on behalf of Teva Neuroscience, Inc. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]